A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Dickey, John B.Albert, Elisabeth
Badr, Mai
Laraja, Kristin M.
Sena, Laureen M.
Gerson, David S.
Saucedo, Jason E.
Qureshi, Waqas
Aurigemma, Gerard P.
UMass Chan Affiliations
Department of Pediatrics, Division of Pediatric CardiologyDepartment of Medicine, Division of Cardiovascular Medicine
Document Type
Response or CommentPublication Date
2021-09-01Keywords
SARS-CoV-2COVID-19
vaccines
myocarditis
Cardiology
Cardiovascular Diseases
Immunology and Infectious Disease
Infectious Disease
Virus Diseases
Metadata
Show full item recordAbstract
Wide availability of the 3 vaccines approved by the U.S. Food and Drug Administration for emergency use against SARS-CoV-2 has led to reports of adverse reactions not seen during clinical trials: We now report a series of patients who developed CMR-proven myocarditis shortly after vaccination.Source
Dickey JB, Albert E, Badr M, Laraja KM, Sena LM, Gerson DS, Saucedo JE, Qureshi W, Aurigemma GP. A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging. 2021 Sep;14(9):1862-1863. doi: 10.1016/j.jcmg.2021.06.003. Epub 2021 Jun 16. PMID: 34246585; PMCID: PMC8219373. Link to article on publisher's site
DOI
10.1016/j.jcmg.2021.06.003Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27508PubMed ID
34246585Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.jcmg.2021.06.003